SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity.
about
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol
P2860
SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
SH003 enhances paclitaxel chem ...... h inhibition of MDR1 activity.
@en
type
label
SH003 enhances paclitaxel chem ...... h inhibition of MDR1 activity.
@en
prefLabel
SH003 enhances paclitaxel chem ...... h inhibition of MDR1 activity.
@en
P2093
P2860
P1476
SH003 enhances paclitaxel chem ...... h inhibition of MDR1 activity.
@en
P2093
Hee Jae Jang
Hee Jae Lee
Hyeong Sim Choi
Min Kyoung Kim
Seong-Gyu Ko
Seung Hee Moon
Sung-Gook Cho
P2860
P2888
P356
10.1007/S11010-016-2875-Y
P577
2016-11-16T00:00:00Z
P6179
1044438326